Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8951230 | Journal of Vascular Surgery | 2018 | 12 Pages |
Abstract
Consistent with the introduction of a novel therapy, the presentation of failure modes of EVAS over time was inevitable. Using detailed imaging as well as engineering and statistical analysis, we were able to understand risk factors for adverse events specific to EVAS and defined those patients best suited for Nellix. With this EVAS-specific approach to defining IFU, on-IFU patients were identified as those with large aneurysms with little thrombus that would be prone to type II endoleaks and sac expansion with traditional devices. When treated with Nellix, these patients were predicted to experience exceptional results, especially with regard to a low composite endoleak rate and low all-cause mortality.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jeffrey P. MD, John S. MD, Jose MD, Sajjad MD, Christopher MD, Clifford J. MD, Homayoun MD, Robert MD,